Results 11 to 20 of about 1,293,284 (282)

The economic cost of cancer treatment in Iran

Journal of Education and Health Promotion, 2023
BACKGROUND: With more than 12 million new cases of cancers and nearly 7.6 million deaths worldwide in 2020, cancer is currently the third leading cause of mortality in the world.
Alireza Jabbari, Marziye Hadian, Elaheh Mazaheri, Zahra Khakdel Jelodar   +3 more
doaj   +1 more source

Epilepsy-Related Direct Medical and Direct Non-Medical Cost in Adult Patients Living with Epilepsy at a Tertiary Neurology Center in Rwanda

ClinicoEconomics and Outcomes Research, 2023
Up to one in four patients living with epilepsy (PwE) mentions financial constraints as a reason for loss to follow-up at the Ndera tertiary neuropsychiatry hospital. Therefore, we evaluated the annual direct medical cost (DMC) and direct non-medical cost (DnMC) of epilepsy and calculated costs assuming different follow-up frequency.DMC data were ...
Dirk E Teuwen, Fidele Sebera, Alphonsine Murekeyiteto, Ieme Garrez, Eduardo Sanchez-Iriso, Josiane Umwiringirwa, Georgette Umuhoza, Paul AJM Boon, Peter Dedeken   +8 more
openaire   +6 more sources

Economic burden of multiple sclerosis: a cross-sectional study in Iran

Health Economics Review, 2022
Background Multiple Sclerosis (MS) is a chronic debilitating disease that imposes a heavy socioeconomic burden on societies. This study aimed to determine the economic burden of MS on patients using the first (CinnoVex and ReciGen) and second (Fingolimod
Mehdi Rezaee, Khosro Keshavarz, Sadegh Izadi, Abdosaleh Jafari, Ramin Ravangard   +4 more
doaj   +1 more source

Economic burden of major depressive disorder: a case study in Southern Iran

BMC Psychiatry, 2022
Background Depression disorders are a leading cause of disability in the world which imposes a significant economic burden on patients and societies The present study aimed to determine the economic burden of Major Depressive Disorder (MDD) on the ...
Khosro Keshavarz, Arvin Hedayati, Mojtaba Rezaei, Zahra Goudarzi, Ebrahim Moghimi, Mehdi Rezaee, Farhad Lotfi   +6 more
doaj   +1 more source

ЕSTIMATION OF SOCIO-ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FOR A 5-YEAR PERIOD: A REGIONAL ASPECT

Фармация и фармакология (Пятигорск), 2021
The aim of the study was to estimate the economic damage by COPD, including direct medical and non-medical costs and indirect costs associated with premature deaths of working-age individuals.Materials and methods.
E. A. Orlova, A. R. Umerova, I. P. Dorfman, M. A. Orlov, M. A. Abdullaev   +4 more
doaj   +1 more source

Households experiencing catastrophic costs due to tuberculosis in Uganda: magnitude and cost drivers

BMC Public Health, 2020
Background Tuberculosis (TB) patients in Uganda incur large costs related to the illness, and while seeking and receiving health care. Such costs create access and adherence barriers which affect health outcomes and increase transmission of disease.
Winters Muttamba, Racheal Tumwebaze, Levicatus Mugenyi, Charles Batte, Rogers Sekibira, Abel Nkolo, Achilles Katamba, Simon Kasasa, Robert Kaos Majwala, Stavia Turyahabwe, Frank Mugabe, Kaggwa Mugagga, Peter Lochoro, Seyoum Dejene, Estella Birabwa, Claudio Marra, Ines Garcia Baena, Bruce Kirenga   +17 more
doaj   +1 more source

Health Technologies Assessment for Orphan Diseases. Example of Social and Economic Burden of Spinal Muscular Atrophy

Педиатрическая фармакология, 2021
Background. Studies of the economic impact of disease on society or the social and economic burden, known as developmental disease cost analysis, are equivalent to public health epidemiological studies.
Aleksei S. Kolbin, Dmitriy V. Vlodavets, Aleksei A. Kurylev, Olga Yu. Germanenko, Natalia Yu. Kolbina   +4 more
doaj   +1 more source

EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control [PDF]

, 2014
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative ...
Andrews, F, Coyle, D, Coyle, K, Crossfield, A, Evers, S, Huic, M, Jones, T, Kalo, Z, Leidl, R, Lester-George, A, Owen, L, Pokhrel, S, Radu-Loghin, C, Rutter, A, Trapero-Bertran, M, Vogl, M, Voko, Z, Vries, HD, West, R   +18 more
core   +8 more sources

Healthcare costs for treating relapsing multiple sclerosis and the risk of progression: a retrospective Italian cohort study from 2001 to 2015 [PDF]

, 2016
Background Disease modifying treatments (DMTs) are the main responsible for direct medical costs in multiple sclerosis (MS). The current investigation aims at evaluating possible associations between healthcare costs for treating relapsing remitting MS ...
Carotenuto, A, Lanzillo, R, Moccia, M, Morra, VB, Palladino, R, Russo, CV, Triassi, M   +6 more
core   +9 more sources

Economic costs of minor depression: a population-based study [PDF]

, 2006
Objective: Although the clinical relevance of minor depression has been demonstrated in many studies, the economic costs are not well explored. In this study, we examine the economic costs of minor depression.
Barrett JE, Callahan C, Central Bureau OF Statistics, Cuijpers P, Greenberg PE, Hakkaart-Van Roijen L, Horwarth E, Langley PC, Oostenbrink JB, Siegel JE, Ter Smitten MH, Torrance GW, World Health Organization   +12 more
core   +3 more sources